Literature DB >> 31244364

Concurrent Adult-Onset Diffuse β-Cell Nesidioblastosis and Pancreatic Neuroendocrine Tumor: A Case Report and Review of the Literature.

Mushfig Orujov1,2, Keith K Lai1, Catherine L Forse1.   

Abstract

Nesidioblastosis is an uncommon cause of organic persistent hyperinsulinemic hypoglycemia in adults. We report a case of adult-onset diffuse β-cell nesidioblastosis in a 49-year-old woman who was status-post Roux-en-Y gastric bypass and distal pancreatectomy for a well-differentiated pancreatic neuroendocrine tumor. While the neuroendocrine tumor was suspected to be an insulinoma, persistent hypoglycemia postoperatively suggested either incomplete resection or a second pancreatic neoplasm. Completion pancreatectomy revealed islet β-cell hyperplasia and nuclear pleomorphism consistent with β-cell nesidioblastosis. The patient's blood glucose levels normalized after completion pancreatectomy. While β-cell nesidioblastosis and insulinomas can coexist in the same patient, pathologists should be aware of β-cell nesidioblastosis as a potential cause for hyperinsulinemic hypoglycemia and should exclude it in patients who have not shown definitive clinical response after surgical excision of a pancreatic neuroendocrine tumor.

Entities:  

Keywords:  Roux-en-Y gastric bypass surgery; adult-onset β-cell nesidioblastosis; pancreatic neuroendocrine tumor; persistent hyperinsulinemic hypoglycemia

Year:  2019        PMID: 31244364     DOI: 10.1177/1066896919858129

Source DB:  PubMed          Journal:  Int J Surg Pathol        ISSN: 1066-8969            Impact factor:   1.271


  2 in total

Review 1.  Case report: composite pancreatic intraductal papillary mucinous neoplasm and neuroendocrine tumor: a new mixed neuroendocrine-non-neuroendocrine neoplasm?

Authors:  Jingci Chen; Pengyan Wang; Ke Lv; Weixun Zhou
Journal:  Diagn Pathol       Date:  2021-11-20       Impact factor: 2.644

2.  Nesidioblastosis and Insulinoma: A Rare Coexistence and a Therapeutic Challenge.

Authors:  Angela Dardano; Giuseppe Daniele; Roberto Lupi; Niccolò Napoli; Daniela Campani; Ugo Boggi; Stefano Del Prato; Roberto Miccoli
Journal:  Front Endocrinol (Lausanne)       Date:  2020-01-24       Impact factor: 5.555

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.